Strategic Acquisition Position Stratos Genomics as a recently acquired, bold partner in advanced sequencing. The Roche acquisition history suggests strong corporate backing and potential for co-development or access to broader distribution channels, enabling sales propositions around SBX technology enhancements and integration with existing Roche workflows.

Cost-Effective Sequencing Highlight ultra-low-cost genome sequencing as a primary value driver. Pitch SBX as a disruptive differentiator for large-scale genomics projects, enabling affordable whole-genome sequencing, which can appeal to research labs seeking budget-friendly expansion of capabilities.

Targeted Applications Emphasize versatility from targeted oncology panels to infectious disease diagnostics. Create tailored pitches showing how SBX can enable faster, single-molecule detection across diverse study designs, appealing to academic labs, biotech firms, and clinical research organizations.

Strategic Partnerships Leverage past collaborations and venture funding momentum to propose co-development or sponsored research opportunities. Approach potential partners with a roadmap for enzyme-related or chemistry collaborations that enhance sequencing accuracy and throughput.

Market Momentum Frame Stratos Genomics within the broader nanopore sequencing ecosystem and Roche’s commitment to advancing SBX chemistry. Position opportunities around integration with nanopore platforms, reagent supplies, and service agreements that support rapid deployment and scale.